OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

NOVARTIS N/  CH0012005267  /

SIX Swiss Exchange
3/10/2025  5:30:23 PM Chg. +0.46 Volume Bid7:30:07 AM Ask7:30:07 AM Market Capitalization Dividend Y. P/E Ratio
101.38CHF +0.46% 4.18 mill.
Turnover: 423.18 mill.		 -Bid Size: 4,329 -Ask Size: 9,382 201.13 bill.CHF - -
GlobeNewswire 2/13 Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthr...
TeleTrader 2/11 Novartis to buy Anthos Therapeutics for up to $3.1B
TeleTrader 1/31 Novartis' Q4 net sales surge 15% to $13.15 billion
TeleTrader 10/29/2024 Novartis' Q2 EPS surge by 116% to $1.58
GlobeNewswire 7/30/2024 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TeleTrader 7/18/2024 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 7/8/2024 Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire 6/26/2024 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 6/13/2024 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 5/29/2024 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 5/13/2024 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
TeleTrader 5/2/2024 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 4/23/2024 Novartis up 5% on upbeat guidance, earnings
TeleTrader 4/23/2024 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 4/16/2024 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire 4/11/2024 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
TeleTrader 4/11/2024 Novartis launches offer for Morphosys at €68 per share
TeleTrader 4/9/2024 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 3/14/2024 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 3/12/2024 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 2/28/2024 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 2/28/2024 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
TeleTrader 2/5/2024 Novartis to acquire MorphoSys for $2.9B
TeleTrader 1/31/2024 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 1/10/2024 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...